At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 518 enrolled
Drug / intervention
Ubrogepant 100 mg +1 moredrug
Likely dose
Ubrogepant 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
In Brief
A Phase 3 clinical trial evaluating Ubrogepant 100 mg and Placebo for Migraine. Completed, enrolled 518 participants across 73 sites.
Detailed Summary
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedJul 30, 2020
Enrollment StartAug 21, 2020
Primary CompletionApr 19, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.9 years ago
Interventions
Ubrogepant 100 mgdrug
For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Placebodrug
For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours